Immunome

$15.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.21 (+1.40%) Today
$0.00 (0.00%) As of 11:00 PM UTC after-hours

Why Robinhood?

You can buy or sell Immunome and other stocks, options, and ETFs commission-free!

About IMNM

Immunome, Inc. operates as a transformative immuno-oncology company. It creates new, safe, and powerful cancer therapies by targeting stem cell and universal cancer antigens. The firm offers discovery engine that enables the simultaneous discovery of novel tumor antigens and the cognate native human antibodies that target those antigens. The company was founded by Scott K. Dessain and Gregory P. Licholai on March 2, 2006 and is headquartered in Exton, PA. The listed name for IMNM is Immunome, Inc. Common Stock.

CEO
Purnanand D. Sarma
Employees
21
Headquarters
Exton, Pennsylvania
Founded
2006
Market Cap
160.44M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
141.32K
High Today
$15.37
Low Today
$15.00
Open Price
$15.37
Volume
84.35K
52 Week High
$16.77
52 Week Low
$9.28

Collections

IMNM Earnings

-$7.52
-$5.01
-$2.51
$0.00
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 16, After Hours

You May Also Like

BMAR
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure